Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
SBFM
Sunshine Biopharma, Inc.
SBFM-PL4 is described as a first-in-class antiviral small-molecule protease inhibitor, aligning with antiviral small-molecule therapeutics.
|
$6.38M |
$1.42
+1.80%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$6.30M |
$1.48
+4.61%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$6.14M |
$7.73
+5.89%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$6.11M |
$5.68
+5.19%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$5.94M |
$3.75
-2.97%
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$5.78M |
$0.04
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$5.76M |
$3.56
+23.61%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$5.65M |
$0.84
-5.92%
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$5.55M |
$1.41
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$5.32M |
$3.29
+0.61%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.32M |
$1.65
-0.30%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$5.24M |
$0.44
+1.14%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$5.23M |
$20.87
-6.41%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$5.07M |
$1.53
+4.42%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$4.51M |
$2.85
+2.33%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$4.33M |
$0.82
+4.72%
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$4.28M |
$5.95
-0.50%
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$4.23M |
$0.46
+5.42%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$4.21M |
$1.28
+7.08%
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$4.20M |
$1.96
+2.08%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$4.10M |
$0.04
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$4.09M |
$1.37
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.03M |
$0.64
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$3.81M |
$0.86
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.76M |
$0.94
-0.04%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.94M |
$0.59
-0.90%
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.78M |
$1.29
+4.03%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.38M |
$0.01
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$2.24M |
$5.16
-1.62%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.18M |
$0.40
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$1.98M |
$0.05
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$1.88M |
$0.15
+162.03%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.69M |
$0.35
+3.90%
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.59M |
$0.93
+10.81%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.56M |
$5.95
+0.17%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.45M |
$1.36
+2.26%
|
Showing page 24 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
